Physician profile
Kenneth Sands
NPI 1669449575
$407,284.36
in general payments reported to CMS, 2019-2025
16 companies · $37K in 2025
The $37K reported for 2025 was more than what 94% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $35K · 2021: $54K · 2022: $82K · 2023: $43K · 2024: $48K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $82K · Consulting Fee: $31K · Travel and Lodging: $13K · Food and Beverage: $1,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $81,529.49 |
| Consulting Fee | $31,200.00 |
| Travel and Lodging | $12,507.50 |
| Food and Beverage | $1,970.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $354,158.51 | 2019-2025 | Djo Surgical |
| Maxx Orthopedics, INC. | $28,946.47 | 2019-2023 | |
| Medacta USA, INC. | $12,067.03 | 2023-2025 | Amistem, Gmk Sphere, Mpact |
| Smith+Nephew, INC. | $5,588.09 | 2019-2020 | |
| Arthrex, INC. | $4,439.20 | 2019-2024 | Arthrex |
| Reel Surgical, INC. | $1,292.73 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $207.87 | 2021-2025 | Exparel, Iovera, Zilretta |
| Paratek Pharmaceuticals, INC. | $125.00 | 2024 | Nuzyra |
| Stryker Corporation | $117.03 | 2025 | Pangea |
| Ermi LLC | $116.39 | 2019-2022 | |
| Think Surgical, INC. | $92.18 | 2023 | |
| Embody, INC. | $54.49 | 2022 | |
| Theragen, INC. | $34.86 | 2019-2020 | |
| Pacira Therapeutics, INC. | $26.86 | 2020-2021 | |
| Nextstep Arthropedix, LLC | $13.90 | 2023 | Insitu Hip System |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $3.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Sands listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.